The Zhitong Finance App learned that on November 19, Genting Xinyao (01952.HK) announced that the VIS-101 phase IIb Ascend clinical study to treat wet age-related macular degeneration (wet AMD) had completed the first patient administration.

Zhitongcaijing · 2d ago
The Zhitong Finance App learned that on November 19, Genting Xinyao (01952.HK) announced that the VIS-101 phase IIb Ascend clinical study to treat wet age-related macular degeneration (wet AMD) had completed the first patient administration.